The University of Arizona has licensed a new technology for measuring brain chemistry to startup Knowmad Technologies. The invention enables researchers to monitor neurotransmitters in real-time in targeted regions of the brain simultaneously.

Scientists at the University of Arizona College of Medicine – Phoenix, in partnership with the University of Luxembourg, have developed a new instrument for studying a biological model of the human gastrointestinal tract that mimics the actual conditions and processes that occur within the intestine.

Using the Lean Launch curriculum, the UA NSF I-Corps program provides up to $2,250 in funding to help entrepreneurial teams with innovative technologies learn about their customers. Applications for the next cohort are due on June 24, 2016.

VIDEO: Before he died unexpectedly, Alan Wall had an idea for a more efficient and less expensive way to clean chillers, and it stands as an example of how innovation can happen across the UA.

Parkinson’s disease often requires long-term use of levodopa, a therapy that can induce dyskinesia. To both treat and prevent levodopa-induced dyskinesia, two UA researchers have repurposed ketamine to improve Parkinson’s patients’ health and wellbeing.

UA faculty perform over $600 million in research each year, and often develop new inventions. TLA, via its Asset Development Program, puts resources toward preparing these unpolished inventions for the market.

The UA has signed an exclusive license agreement for a molecular imaging technology, Beta Emission Tomography invented by Dr. Harrison Barrett, to Lightpoint Medical of Chesham, England.

On April 25, 2016, TLA held its third annual awards event. The I-Squared Awards for Innovation and Impact honored those whose work directly affects the quality of life for people in Tucson, across Arizona and throughout the world.

Akhu Therapeutics has licensed a UA technology that is targeted to allow doctors to relieve the symptoms of acute depression in a fraction of the time required for current therapies.

TLA is working with College of Medicine researchers on bringing a new snakebite treatment to market that may serve as a “bridge” to buy time until medical care is available.